Osteoporosis Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) – Estimates DelveInsight | Transcenta Holding, Celltrion, Sandoz, Samsung Bioepis, Alvotech, MAbxience

Osteoporosis Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) - Estimates DelveInsight | Transcenta Holding, Celltrion, Sandoz, Samsung Bioepis, Alvotech, MAbxience
Delveinsight Business Research LLP
As per DelveInsight, the Osteoporosis Market is anticipated to evolve immensely in the coming years owing to the rise in the number of prevalent cases of Osteoporosis in the 7MM and the launch of new therapies in the market.

DelveInsight’s “Osteoporosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Osteoporosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Osteoporosis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Osteoporosis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Osteoporosis: An Overview

Osteoporosis is defined as a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. This well-established definition, developed by the international consensus in 1993, captures two important characteristics of the disease: its adverse effects on bone mass and microstructure, and the clinical outcome of fracture.

It is a condition that often remains undiagnosed until it manifests as a low-trauma fracture of the hip, spine, proximal humerus, pelvis, and/or wrist, which frequently leads to hospitalization. Estrogen is considered important in maintaining bone density in women. When estrogen levels drop after menopause, loss of bone density accelerates. During the first 5 to 10 years after menopause, women can suffer up to 2-4% loss of bone density per year.

The causes of osteoporosis include hyperparathyroidism, hyperglycemia, medications, smoking, alcohol use, oxidative stress, inflammation, calcium deficiency, menopause, etc. The most common symptom of osteoporosis is a vertebral compression fracture or hip fracture. The compression fractures in the spine, caused by weakened vertebrae can lead to pain in the mid-back area. The fractures often stabilize on their own, and the pain goes away, but sometimes the pain persists because the crushed bone continues to move around and break. The symptoms include loss of height, back pain, increased number of bed days, depression, etc.

The key risk factors for osteoporosis include genetics, lack of exercise, lack of calcium and vitamin D, personal history of fracture as an adult, cigarette smoking, excessive alcohol consumption, history of rheumatoid arthritis, low body weight, and family history of osteoporosis.

Osteoporosis Market Key Facts

  • According to the CDC, in the US, the prevalence of low bone mass, a precursor of Osteoporosis, at either the femur neck or lumbar spine or both among adults aged 50 and over was 43.1% and was higher among women (51.5%) compared with men (33.5%). Osteoporosis prevalence increased from 2007–2008 to 2017–2018 among women, but not men.

  • According to the International Osteoporosis Foundation, in the UK, the prevalence of Osteoporosis in the total population amounted to 5.2%, on par with the EU27+2 average (5.6%). In the UK, 21.9% of women and 6.7% of men aged 50 years or more were estimated to have Osteoporosis. Hip fracture is the most serious consequence of Osteoporosis in terms of morbidity, mortality, and health care expenditure.

  • According to a study conducted by Bolster et al. titled “Osteoporosis” states that about 8 million women and 2 million men in the United States have osteoporosis. In addition, more than 95% of women and about 80% of men are primary osteoporosis. Whereas, secondary osteoporosis is less than 5% in women and about 20% in men.

  • DARBA et al. conducted a study titled “Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain,” which found the prevalence rate of postmenopausal osteoporosis (PMO) of approximately 25% for women aged 60–69 years and 40% for those aged 70–79 years was in Spain.

Osteoporosis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Osteoporosis pipeline therapies. It also thoroughly assesses the Osteoporosis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Osteoporosis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Osteoporosis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Osteoporosis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Osteoporosis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Osteoporosis Epidemiology, Segmented as –

  • Prevalence of Osteoporosis

  • Prevalence of Primary Osteoporosis

  • Prevalence of Secondary Osteoporosis 

  • Incidence of Osteoporotic Fractures

  • Diagnosed Prevalence of Osteoporosis

  • Gender-specific Prevalence of Osteoporosis

  • Osteoporosis-related comorbidities

Osteoporosis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Osteoporosis market or expected to be launched during the study period. The analysis covers the Osteoporosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Osteoporosis drugs based on their sale and market share.

The report also covers the Osteoporosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Osteoporosis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Osteoporosis Market Will Evolve and Grow by 2032 @ 


Osteoporosis Therapeutics Analysis

The treatment of osteoporosis involves treating and preventing fractures and using medicines to strengthen the weak bones. According to the International Osteoporosis Foundation, for patients at high risk, drug treatments are needed to effectively reduce the risk of broken bones due to osteoporosis. Treatments have been shown to reduce the risk of hip fracture by up to 40%, vertebral fractures by 30-70%, and, with some medications, reduce the risk of non-vertebral fractures by 15-20%.

The treatment landscape of osteoporosis comprises mostly pharmacological therapies, which is further characterized as anti-resorptive agents (i.e., bisphosphonates, estrogen agonist/antagonists (EAAs), estrogens, calcitonin, and denosumab), anabolic agents (i.e., teriparatide and abaloparatide), and mixed agents (i.e., Romosozumab). Apart from the mentioned pharmacotherapies, there are several other anti-resorptive treatment options to treat osteoporosis, such as estrogen replacement and selective estrogen receptor modulators, which further comprise of raloxifene, lasofoxifene, and bazedoxifene. In addition, a few dietary supplements such as calcium and vitamin D also provide benefits to patients with osteoporosis.

To further improve the treatment outlook, several major pharma and biotech companies are developing therapies for Osteoporosis. Currently, Celltrion is leading the therapeutics Osteoporosis drug candidates in the most advanced stage of clinical development.

Osteoporosis Companies Actively Working in the Therapeutics Market Include

  • Shanghai JMT-Bio Inc.

  • Transcenta Holding

  • Celltrion

  • Sandoz

  • Enzene Biosciences

  • Fresenius Kabi

  • Gedeon Richter

  • Samsung Bioepis

  • Alvotech

  • MAbxience

  • Shanghai Henlius Biotech

And Many Others

Emerging and Marketed Osteoporosis Therapies Covered in the Report Include:

  • JMT 103: Shanghai JMT-Bio Inc.

  • TST-002: Transcenta Holding

  • CT-P41: Celltrion

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Osteoporosis Competitive Intelligence Analysis

4. Osteoporosis Market Overview at a Glance

5. Osteoporosis Disease Background and Overview

6. Osteoporosis Patient Journey

7. Osteoporosis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Osteoporosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Osteoporosis Unmet Needs

10. Key Endpoints of Osteoporosis Treatment

11. Osteoporosis Marketed Therapies

12. Osteoporosis Emerging Drugs and Latest Therapeutic Advances

13. Osteoporosis Seven Major Market Analysis

14. Attribute Analysis

15. Osteoporosis Market Outlook (In US, EU5, and Japan)

16. Osteoporosis Companies Active in the Market

17. Osteoporosis Access and Reimbursement Overview

18. KOL Views on the Osteoporosis Market

19. Osteoporosis Market Drivers

20. Osteoporosis Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @




About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Hypereosinophilic Syndrome Market

“Hypereosinophilic Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hypereosinophilic Syndrome market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hypereosinophilic Syndrome market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research